Elicio (ELTX) Director Ashe Carol Gail Receives 21,750-Share Award

What Happened

• Ashe Carol Gail, a director of Elicio Therapeutics (ELTX), was granted a derivative equity award representing 21,750 shares on 2026-08-31. The grant is reported as a $0 acquisition (no immediate cash purchase).
• The award is the annual non-employee director equity grant and will vest and become exercisable in full on the earlier of (A) August 31, 2027 (one year after grant) or (B) the Issuer’s 2027 annual meeting, provided Ms. Gail continues to serve through the vesting date. The filing notes no additional equity award will be made in connection with the 2026 annual meeting.

Key Details

• Transaction date: 2026-08-31; Form 4 filed: 2026-09-02.
• Transaction type/code: Award/Grant (derivative) — 21,750 shares at $0.00 per share (no immediate cash value).
• Shares owned after transaction: Not specified in the filing.
• Footnote: Vesting in full on earlier of Aug 31, 2027 or 2027 annual meeting, subject to continued service; this is the routine annual director award.
• Filing timeliness: Filing date is shown as 2026-09-02; the Form 4 covers the 2026-08-31 grant.

Context

• This is a standard director compensation award (equity grant) intended for retention and alignment with shareholders; it does not represent an open-market purchase or sale and carries no immediate cash value. Such awards are common and typically viewed as routine rather than a direct bullish or bearish signal.